Study of WGc-0201 plus tislelizumab for liver cancer after surgery or ablation
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of two drugs (WGc-0201 and tislelizumab) after liver cancer has been removed or destroyed by ablation (radiofrequency or microwave). It aims to see if this treatment can lower the chance of the cancer coming back in people who have a high risk of recurrence and are also carriers of hepatitis B.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with hepatocellular carcinoma (a type of liver cancer).
- You must have had surgery to remove the cancer or ablation treatment (radiofrequency or microwave) 4 to 12 weeks before joining.
- After surgery, your doctor must confirm the margins are clear (no cancer at the edge of the removed tissue), or after ablation, all tumor areas must show no signs of active cancer on imaging.
- You must be positive for hepatitis B surface antigen (a blood test marker showing hepatitis B infection).
- You must not have cancer that has spread to other organs (no distant metastasis).
- You must not have severe fluid build-up in the abdomen (clinically significant ascites) or a history of hepatic encephalopathy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs: tislelizumab (an immunotherapy that helps your immune system attack cancer) and huaier granule (a traditional Chinese medicine extract). It is for people with advanced liver cancer that cannot be removed by surgery and who have not had other systemic treatments before.
This trial tests a new immunotherapy drug (GKL-006) combined with a standard treatment called TACE (which blocks blood flow to the tumor) for people with liver cancer that cannot be removed by surgery. The goal is to see if adding this drug helps shrink tumors more than TACE alone.
This trial tests whether combining an immunotherapy drug (sintilimab) with a targeted therapy (lenvatinib) after surgical removal of liver cancer can help prevent the cancer from coming back. It is for patients whose tumors show a specific blood vessel pattern called VETC.
This trial tests whether combining two targeted drugs (lenvatinib and tislelizumab) works better than lenvatinib alone for people with advanced liver cancer whose disease worsened after prior treatment with an immunotherapy and a blood vessel growth blocker (bevacizumab).
This trial tests a combination of three drugs (TPST-1120, atezolizumab, and bevacizumab) for people with advanced liver cancer that hasn't been treated before. The goal is to see if adding this new drug to the standard immunotherapy and targeted therapy helps shrink or control the cancer better.
This study looks at combining TACE (a procedure that delivers chemotherapy directly to the liver) with two newer drugs — tislelizumab (immunotherapy) and lenvatinib (targeted therapy) — for people with advanced liver cancer. The goal is to see how well this combination works when used together.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.